POS1280 EFFECTS OF ANTI-SARS-CoV-2 VACCINATION ON SAFETY AND DISEASE EXACERBATION IN BEHCET’S DISEASE PATIENTS: A SINGLE CENTRE STUDY

Background Pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome – 2 (SARS-CoV-2), has become a major global health issue since December 2019. Patients affected systemic rheumatic disorders represent high-risk group for COVID-19. During the COVID-19 pandemic, vaccination one cornerstones fight against this disease. The EULAR and ACR recommend in all patients with rheumatological diseases. There is paucity data regarding safety vaccines musculoskeletal diseases such as Behçet’s (BD). Objectives In study, we evaluated tolerance vaccines, post-vaccine BD exacerbation discontinuation therapy retrospectively examining our cohort, from patients’ perspective. Methods We 450 followed clinic using hospital records formed retrospective cohort who met International Study Group (ISG) criteria. status, vaccine type (inactivated or mRNA), side effects exacerbations, drug compliance, change treatment after exacerbation, occurrence were interviewing over phone face to face. Patient demographics, comorbid diseases, active treatments collected records. Disease activity was measured BSAS BDCAF form. Results Our consisted total patients. Two hundred eighty seven had at least 1 dose vaccine. Of number (n= 639), 379 (59%) Pfizer-BionTech 257 (41%) Sinovac vaccines. side-effects first, second, third fourth 151 (52.6%), 135 (47%), 29 (10.1%) 3 (1%), respectively. Behçet flare 16 (22.9%) (33.3%), most common arm pain, joint pains arthritis, malaise, while exacerbations arthralgia oral aphthae, papulopustular eruption compared terms effects, there significant difference 1st (p<0.001) 2nd doses (p<0.001), but no found 3rd (p= 0.353) (Table 1). When 0.417), 0.465) 0.565). Only 4 (1.3%) developed organ involvement Anterior uveitis patients, panuveitis patient, deep vein thrombosis patient. Table 1. Side according COVID vaccine, n/ N afterfirst p second afterthird 47 (39.5 ) <0.001 34 (30.1 9 (36 0.353 None - Biontech 104 (61.9 101 (63.1 20 (47.6 (33.3) n/N Flare first seconddose 13 (11.0% 0.417 18 (15.9% 0.465 5 (20.0% 0.565 24 (14.3% 31 (19.4% 11 (26.2 % Conclusion conclusion, study shows that well tolerated predominantly includes mucocutaneous articuler findings, are rare. According although more Pfizer-BioNTech group, between Disclosure Interests declared